Suppr超能文献

持续评估法,具有多重毒性限制。

Continual reassessment method with multiple toxicity constraints.

机构信息

Department of Biostatistics, Columbia University, New York, NY 10032, USA.

出版信息

Biostatistics. 2011 Apr;12(2):386-98. doi: 10.1093/biostatistics/kxq062. Epub 2010 Sep 28.

Abstract

This paper addresses the dose-finding problem in cancer trials in which we are concerned with the gradation of severe toxicities that are considered dose limiting. In order to differentiate the tolerance for different toxicity types and grades, we propose a novel extension of the continual reassessment method that explicitly accounts for multiple toxicity constraints. We apply the proposed methods to redesign a bortezomib trial in lymphoma patients and compare their performance with that of the existing methods. Based on simulations, our proposed methods achieve comparable accuracy in identifying the maximum tolerated dose but have better control of the erroneous allocation and recommendation of an overdose.

摘要

本文探讨了癌症试验中的剂量探索问题,我们关注的是被认为是剂量限制的严重毒性的分级。为了区分不同毒性类型和等级的耐受能力,我们提出了一种新的连续再评估方法的扩展,该方法明确考虑了多个毒性约束。我们将提出的方法应用于淋巴瘤患者硼替佐米试验的重新设计,并将其性能与现有方法进行比较。基于模拟,我们提出的方法在确定最大耐受剂量方面具有相当的准确性,但在错误分配和推荐超量方面具有更好的控制。

相似文献

1
Continual reassessment method with multiple toxicity constraints.
Biostatistics. 2011 Apr;12(2):386-98. doi: 10.1093/biostatistics/kxq062. Epub 2010 Sep 28.
2
Calibration of prior variance in the Bayesian continual reassessment method.
Stat Med. 2011 Jul 30;30(17):2081-9. doi: 10.1002/sim.4139. Epub 2011 Mar 17.
4
Review. Clinical pharmacokinetics of bortezomib.
In Vivo. 2007 Mar-Apr;21(2):273-8.
5
Identifying a maximum tolerated contour in two-dimensional dose finding.
Stat Med. 2017 Jan 30;36(2):242-253. doi: 10.1002/sim.6918. Epub 2016 Feb 22.
7
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27.
8
Simple benchmark for complex dose finding studies.
Biometrics. 2014 Jun;70(2):389-97. doi: 10.1111/biom.12158. Epub 2014 Feb 25.
9
Treatment of multiple myeloma: 2009 update.
Prescrire Int. 2009 Dec;18(104):263-6.
10

引用本文的文献

1
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes.
Stat Biopharm Res. 2025;17(1):36-45. doi: 10.1080/19466315.2023.2288013. Epub 2024 Jan 5.
2
MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials.
Stat Biopharm Res. 2024;16(3):305-314. doi: 10.1080/19466315.2024.2368802. Epub 2024 Jul 31.
3
MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities.
J Immunother Precis Oncol. 2024 Aug 19;7(3):159-167. doi: 10.36401/JIPO-23-35. eCollection 2024 Aug.
4
6
Statistical and practical considerations in planning and conduct of dose-optimization trials.
Clin Trials. 2024 Jun;21(3):273-286. doi: 10.1177/17407745231207085. Epub 2024 Jan 19.
7
Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer.
Int J Biostat. 2022 Nov 17;19(1):163-176. doi: 10.1515/ijb-2022-0023. eCollection 2023 May 1.
8
Mathematical Modelling for Optimal Vaccine Dose Finding: Maximising Efficacy and Minimising Toxicity.
Vaccines (Basel). 2022 May 11;10(5):756. doi: 10.3390/vaccines10050756.
9
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens.
Stat Med. 2021 Oct 15;40(23):5096-5114. doi: 10.1002/sim.9113. Epub 2021 Jul 14.
10
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
JCO Precis Oncol. 2021 Feb 1;5:317-324. doi: 10.1200/PO.20.00379. eCollection 2021 Jan.

本文引用的文献

1
Stochastic approximation with virtual observations for dose-finding on discrete levels.
Biometrika. 2010 Mar;97(1):109-121. doi: 10.1093/biomet/asp065. Epub 2009 Dec 7.
2
Risk-group-specific dose finding based on an average toxicity score.
Biometrics. 2010 Jun;66(2):541-8. doi: 10.1111/j.1541-0420.2009.01297.x. Epub 2009 Jul 23.
3
Model calibration in the continual reassessment method.
Clin Trials. 2009 Jun;6(3):227-38. doi: 10.1177/1740774509105076.
4
Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.
Biometrics. 2009 Mar;65(1):307-15. doi: 10.1111/j.1541-0420.2008.01045.x. Epub 2008 May 13.
5
Dose-finding in phase I clinical trials based on toxicity probability intervals.
Clin Trials. 2007;4(3):235-44. doi: 10.1177/1740774507079442.
6
The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
Biometrics. 2007 Mar;63(1):173-9. doi: 10.1111/j.1541-0420.2006.00666.x.
7
A simple technique to evaluate model sensitivity in the continual reassessment method.
Biometrics. 2002 Sep;58(3):671-4. doi: 10.1111/j.0006-341x.2002.00671.x.
8
On the use of nonparametric curves in phase I trials with low toxicity tolerance.
Biometrics. 2002 Mar;58(1):237-40. doi: 10.1111/j.0006-341x.2002.00237.x.
9
Accelerated titration designs for phase I clinical trials in oncology.
J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47. doi: 10.1093/jnci/89.15.1138.
10
A random walk rule for phase I clinical trials.
Biometrics. 1997 Jun;53(2):745-60.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验